The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer.

Hailun XieGuotian RuanLishuang WeiLi DengQi ZhangYizhong GeMengmeng SongXi ZhangShiqi LinXiaoyue LiuMing YangChunhua SongXiaowei ZhangHan Ping Shi

Published in: Journal of cachexia, sarcopenia and muscle (2023)

The IBI was independently associated with overall survival, 90-day outcomes, length of hospitalization, hospitalization expenses and cachexia in NSCLC patients. As an optimal systemic inflammation biomarker, the IBI has broad clinical application prospects in predicting the prognosis of patients with NSCLC.

Keyphrases

small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
advanced non small cell lung cancer
prognostic factors
insulin resistance
adipose tissue